For the year ending 2025-12-31, CYCN had $8K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -3,528 | -3,057 |
| Gain on disposal of discontinued operations | - | 0 |
| Gain from settlement of account payable | 0 | 363 |
| Impairment loss | - | 0 |
| Share-based compensation expense | 441 | 625 |
| Accounts receivable | 444 | 556 |
| Prepaid expenses | -37 | -21 |
| Other current assets | -5 | 5 |
| Operating lease assets | - | 0 |
| Other assets | - | 0 |
| Accounts payable | 118 | -445 |
| Accrued research and development costs | 146 | -38 |
| Accrued expenses and other current liabilities | -89 | -515 |
| Net cash used in operating activities | -3,314 | -4,333 |
| Net proceeds from disposal of discontinued operations | - | 0 |
| Net cash provided by investing activities | - | 0 |
| Proceeds from atm | 2,077 | - |
| Proceeds from private placement | 1,375 | 0 |
| Proceeds from exercises of stock options and espp | - | 0 |
| Issuance costs paid for private placement | -130 | - |
| Net cash provided by financing activities | 3,322 | 0 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | -6 |
| Net increase (decrease) in cash and cash equivalents | 8 | -4,339 |
| Cash and cash equivalents, beginning of period | 3,232 | 7,571 |
| Cash and cash equivalents, end of period | 3,240 | 3,232 |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)